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A 41-year-old female with a history of migraine had no previous ocular problems except myopia with
spherical refraction of 2.25 D OD and 1.75 D OS. She experienced sudden onset of bilateral blurred
vision, ocular fullness sensation, and headache after undergoing topiramate therapy for 7 days (50 mg/
day). Her visual acuities with the presenting glasses were 20/200 OD and 20/50 OS. Intraocular pressures
(IOPs) were 44 mmHg OD and 49 mmHg OS, respectively. Autorefraction measurement showed spherical
refraction of 5.25 D OD and 4.75 D OS. Best-corrected visual acuities were 20/20 for both oculus
dexter (OD) and oculus sinister (OS). Slit-lamp examination revealed bilateral conjunctival chemosis,
very shallow anterior chambers, forward displacement of lenseiris diaphragm, round and sluggishly
reacting pupils, and closed angles on gonioscopy. A B-scan ultrasound displayed choroidal thickening in
both eyes. An ultrasound biomicroscopy demonstrated bilateral 360 ciliochoroidal effusions with for-
ward rotation of ciliary body but no pupillary block. Impression of topiramate-induced bilateral angle-
closure glaucoma and acute myopic shift was recorded. She was advised to discontinue topiramate
immediately and was administered antiglaucoma medication and mydriatics. Two days later, IOP
returned to normal limits and myopic shift resolved after 1 week. Her visual acuity with previous glasses
improved to 20/20 OU. In addition, choroidal effusions also subsided gradually. The presented case
highlights the possible side effects of topiramate, offers management and suggestion for such a con-
dition, and brings awareness to sulfa drug complications.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Topiramate, a sulfamate-substituted monosaccharide, is gen-
erally prescribed as an antiepileptic and antidepressant medication.
Several mechanisms elicit its antiseizure effect. For example, the
drug serves as a state-dependent blocker of sodium channels,
enhances g-aminobutyric acid (GABA)-mediated chloride ﬂuxes
across the postsynaptic membrane, provides positive modulation
of GABA-A receptors, and produces a mild effect by inhibiting the
activity of carbonic anhydrase. Treatment with topiramate is found
to be useful in migraine, bipolar disorder, weight loss, andiﬁc Joint Glaucoma Congress,
s of interest relevant to this
ology, Taipei City Hospital,
n District, Taipei City 10629,
e Ophthalmologic Society of Taiwneuropathic pain.1 However, in July 2001, Banta et al. ﬁrst reported
a case of secondary angle-closure glaucoma associated with top-
iramate use. Thereafter, several cases of ocular adverse reaction
related to topiramate administration have been published.2 During
the past 10 years, there were 39 case reports throughout the world.
Although few cases were published in Chinese population, few such
case reports were proposed in Taiwan population as well. There-
fore, we herein present a case to highlight the possible side effects
of topiramate, offer management and suggestion for such con-
dition, and bring awareness to sulfa drug complications.
2. Case report
A 41-year-old healthy female presented to our hospital with
sudden onset of bilateral ocular pain, ocular fullness sensation,
blurred vision, and headache. On initial examination, her visual
acuity with presenting glasses was 20/200 in the right eye and 20/
50 in the left eye. Intraocular pressures (IOPs) as measured using an
air puff tonometer were 44 mmHg OD and 49 mmHg OS. Central
corneal thickness of both eyes was 540 mm (oculus dexter or OD)an. Published by Elsevier Taiwan LLC. All rights reserved.
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showed spherical refraction of 5.25 D OD and 4.75 D OS with
acute myopic shift of 3.00 D in both eyes. The best-corrected visual
acuity (BCVA) was 20/20 for both eyes. A slit-lamp examination
revealed bilateral conjunctival chemosis and injection. Shallow
anterior chambersmeasured using a Zeiss IOLMasterwere 2.20mm
OU (average anterior chamber depth of adults: 3.15 mm) with iri-
docorneal touch for 360 and forward displacement of lenseiris
diaphragm. Round and sluggishly reacting pupils without dilata-
tion was also observed (Fig. 1A and B). Axial length was 23.80 mm
(OD) and 23.78 mm (OS). Average corneal curvature measured
44.23/44.82 D (OD) and 43.60/44.94 D (OS). Cystic corneal edema,
peripheral anterior synechiae, or cellular inﬂammation in the
anterior chambers was not detected. Gonioscopy showed closed
angles in both eyes (Fig. 1C). A fundus photograph revealed normal
retina and cup-disk ratio of 0.4 in both eyes.
Her medical history showed no previous ocular problems except
myopia with spherical refraction of 2.25 D OD and 1.75 D OS.
Shallow anterior chamber depth was noted due to forward dis-
placement of lenseiris diaphragm during the slit-lampFig. 1. At presentation, slit-lamp photograph revealed (A) shallow anterior chamber and fo
marked shallow anterior chamber depth (2.20 mm) in both eyes, and (C) bilateral closed aexamination. She had a past history of migraine under medication
control. One week before her presenting symptoms, she was
administered 50-mg topiramate daily for her migraine headache.
She claimed no trauma history recently. There was no family his-
tory of glaucoma and her visual ﬁeld was within normal limit. A B-
scan ultrasound (SONOMED, B-5500) was performed, which
revealed annular peripheral choroidal effusions in both eyes
(Fig. 2A), while the lens thickness of both eyes was about 4.0 mm.
At the same time, no characteristic T sign was demonstrated, and
posterior scleritis (PS) is unlikely. Ultrasound biomicroscopy (UBM)
(SONOMED, VuMAX) was arranged, which showed closed irido-
corneal angles, bilateral 360 ciliochoroidal effusions, swelling and
forward rotation of ciliary body; however, no pupillary block was
seen (Fig. 2B).
She was advised to discontinue topiramate immediately and
was prescribed antiglaucoma medication including intravenous
infusion of mannitol, topical antiglaucoma eye drops, and mydri-
atics with 1% tropicamide b.i.d. (twice a day). Initial antiglaucoma
eye drops were 0.5% timolol b.i.d. and 1% brinzolamide t.i.d. (thrice
a day). The following day, much severe conjunctival chemosis andrward displacement of the lenseiris diaphragm, (B) severe conjunctival chemosis, and
ngles on gonioscopy. OD ¼ oculus dexter; OS ¼ oculus sinister.
Fig. 2. (A) On examination, B-scan ultrasound showed peripheral choroidal thickening and effusion (black arrows) in both eyes. (B) Ultrasound biomicroscopy (UBM) demonstrated
ciliochoroidal effusions (white arrows) and forward rotation of edematous ciliary body (asterisks) in both eyes. (C and D) Three weeks later after discontinuation of topiramate, B-
scan and UBM showed resolved choroidal effusions and edema of ciliary body in both eyes.
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25 and 30 mmHg, respectively. We stopped the brinzolamide usage
due to suspicion of idiosyncratic reaction.
Two days later, IOP returned to normal limits with resolution of
the conjunctival chemosis. On Day 7, her myopic shift has resolved,
and her visual acuity with previous glasses improved to 20/20 OU.
Results of B-scan and UBM revealed mild residual choroidal effu-
sions in both eyes that subsided 3 weeks later (Fig. 2C and D).
However, relative shallow anterior chamber depth was noted at her
3-month follow-up (2.68 mm OD and 2.62 mm OS). At this point,
the BCVA readings were 20/20 OU, with IOP and anterior chamber
depth remaining stable. Topical aqueous suppressants were
discontinued.
3. Discussion
Bilateral simultaneous secondary acute angle-closure glaucoma
is rare, and has been reported relating to drugs, general anesthesia,
snake bite, microspherophakia, and VogteKoyanagieHarada syn-
drome.3 Among these, sulfonamide drug and its derivatives have
been documented to cause transient myopia, ciliary body edema,
choroidal effusions, and anterior rotation of the lenseiris dia-
phragm inducing secondary angle closure.4
In this case, bilateral acute myopic shift of 3.0 D was noted
besides secondary angle closure. The differential diagnoses were
primary angle-closure glaucoma (PACG), acute attack of chronic
angle-closure glaucoma, PS, and drug-induced secondary angle-
closure glaucoma. Given her younger age and myopic refractive
status, plus no family history, PACG could be excluded. Besides,
rarely are bilateral case and myopic progression reported in pri-
mary angle closure. A few factors, such as no history of glaucoma,
no peripheral anterior synechiae, no progressive cupping of the
optic nerve head, and no characteristic glaucomatous loss of visual
ﬁeld, excluded the possibility of acute attack of chronic angle-
closure glaucoma. PS could give rise to angle-closure glaucoma
without pupillary block due to choroidal effusions. PS is painful and
may be associated with choroidal folds and serous elevation of the
retina. In addition, bilateral PS can occur, but is rare. B-scan ultra-
sonography is quite characteristic, due to the presence of the T sign
that occurs from collection of ﬂuid in the sub-Tenon’s space.
Therefore, PS needs to be considered. Topiramate-induced bilateral
acute angle-closure glaucoma and myopic shift had been reported
in several literatures. There were ocular ﬁndings of high myopia,
shallow anterior chambers with anterior iris and lens displacement,
microcystic edema, elevated IOP, closed anterior chamber angles,
and ciliochoroidal effusions/detachment.4
Topiramate, a sulfa derivative, would cause potentially serious
ocular side effects including blurred vision, acute IOP elevation,
acute myopia, diplopia, nystagmus, and shallow anterior chamber
with angle closure.5 In placebo-controlled trials, myopia was seen
in 1% of children and abnormal vision in 13% of adults. Overall
ocular adverse effects >1% was noted from the literature review.6
These patients were predominantly female (89%) with a mean
age of 34 years. Most cases have been reported to occur within the
ﬁrst 2 weeks (3e21 days) of starting topiramate administration, or
within hours of doubling the doses.7 Few cases were presented as
unilateral episodes.8 Symptoms were bilateral blurred vision, eye
pain, sudden loss of vision with myopic shift, pressure sensation,
headache, nausea, and vomiting. Ocular ﬁndings are high myopia,
shallow anterior chambers with anterior iris and lens displacement,
microcystic edema, elevated IOP, a closed anterior chamber angle,
and a ciliochoroidal effusions/detachment.46
Nevertheless, the eye structures are not the risk factors to
induce the malignant glaucoma after having topiramate. The
underlying mechanism of topiramate-induced acute IOP elevationis not clear yet. It may be an idiosyncratic reaction and can occur in
otherwise normal eyes with normal anterior chamber angles,
resulting in ciliochoroidal effusions with ciliary body swelling and
induce forward rotation of the iriselens diaphragm, causing myo-
pia and angle-closure glaucoma.4,5 Themanagement of topiramate-
related acute angle-closure glaucoma requires immediate cessation
of topiramate, and institution of medical therapy including oral and
topical aqueous suppressants. Use of pilocarpine can lead to further
narrowing of the angles and worsening of signs and symptoms.
Traditional treatment for angle-closure glaucoma such as laser
iridotomy or surgical peripheral iridectomy may not be of value as
precipitating mechanism is not a pupillary block. Topical cyclo-
plegic agents can be given as they lower IOP by relaxing the ciliary
muscle and deepening anterior chamber.48
In our case, we administered intravenous mannitol, topical
aqueous suppressants, and mydriatics for treatment, in addition to
topiramate cessation. Oral acetazolamide, a sulfa-derivative medi-
cation, was avoided as treatment for the elevated IOP, because it has
been reported to cause secondary angle-closure glaucoma.9 Topical
antiglaucoma eye drops were given with 0.5% timolol and 1%
brinzolamide. However, on the next day, conjunctival chemosis
worsened, with only mild improvement in IOP. Brinzolamide
administration was suspected due to its sulfonamide-derived
property, and possible idiosyncratic reactions, although no pre-
vious case reports were presented. As such, it was stopped. Two
days later, her IOP returned to normal ranges with resolution of
the conjunctival chemosis. In our opinion, any systemic or topical
sulfa-derivative drugs should be avoided when clinical suspicion
of topiramate-associated acute angle-closure glaucoma is
encountered.9,10
Topiramate/sulfa-derivative medication can induce ocular
adverse effects of bilateral acute myopia and angle-closure glaucoma
secondary to choroidal effusions.48 Ophthalmologist should be
aware of this potential complication. The quick identiﬁcation of sulfa-
derivative medication and subsequent discontinuation can expedite
resolution of the angle closure. If the causative medication is not
recognized, persistent high IOP may result in permanent visual loss.
Neurologist and psychiatrist prescribing topiramate for their patients
should be alert to such side effects, and be advised immediate referral
to ophthalmology service under clinical suspicion.References
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